The evolution of SARS-CoV-2 seroprevalence in Canada: a time-series study, 2020-2023
This study used data from the COVID-19 Immunity Task Force, which includes CanPath data, to track the prevalence of SARS-CoV-2 antibodies in the Canadian population over the pre-vaccination period, the vaccine rollout, and the emergence of the Omicron variant. By March 2023, over three-quarters of the population had detectable antibodies, with the most substantial increases seen after the arrival of the Omicron variant. However, variations in immunity by age and geography highlight the importance of tailoring public health policies and clinical decisions to local patterns of population immunity, considering factors like potential antibody decline and the emergence of new variants that might evade immunity.
Uncovering the Contribution of Moderate-Penetrance Susceptibility Genes to Breast Cancer by Whole-Exome Sequencing and Targeted Enrichment Sequencing of Candidate Genes in Women of European Ancestry
The aim of this study was to perform a large-scale whole-exome sequencing study, followed by a targeted validation, in breast cancer patients and healthy women of European descent. Using data from 920 CARTaGENE participants and four other sources, the researchers identified 20 novel genes with modest association evidence for overall and subtype-specific breast cancers.